4basebio (XTER:88Q) Receivables Turnover : 4.20 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 4basebio Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. 4basebio's Revenue for the six months ended in Jun. 2023 was €0.28 Mil. 4basebio's average Accounts Receivable for the six months ended in Jun. 2023 was €0.07 Mil. Hence, 4basebio's Receivables Turnover for the six months ended in Jun. 2023 was 4.20.

4basebio Receivables Turnover Historical Data

The historical data trend for 4basebio's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Receivables Turnover Chart

4basebio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Receivables Turnover

2.62

7.61

8.21

5.31

4basebio Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Receivables Turnover	Get a 7-Day Free Trial			2.27	1.93	2.31	1.65	4.20

Competitive Comparison of 4basebio's Receivables Turnover

For the Biotechnology subindustry, 4basebio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4basebio's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where 4basebio's Receivables Turnover falls into.

4basebio Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

4basebio's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as

	Receivables Turnover (A: Dec. 2022 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2022 )	/ (	(Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )
=	0.308	/ (	(0.054	+	0.062)	/	2 )
=	0.308	/	0.058
=	5.31

4basebio's Receivables Turnover for the quarter that ended in Jun. 2023 is calculated as

	Receivables Turnover (Q: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2023 )	/ (	(Accounts Receivable (Q: Dec. 2022 )	+	Accounts Receivable (Q: Jun. 2023 ))	/	count )
=	0.277	/ (	(0.062	+	0.07)	/	2 )
=	0.277	/	0.066
=	4.20

4basebio (XTER:88Q) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

4basebio Receivables Turnover Related Terms

Thank you for viewing the detailed overview of 4basebio's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (XTER:88Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

4BB:UK

Address

25 Norman Way, Over, Cambridge, GBR, CB24 5QE

Website

https://www.4basebio.com

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines